DMBP

Molekulární biofyzika a farmakologie

Ongoing projects

  • Howard Hughes Medical Institute (USA), HHMI, INTNL 55005613
    Platinum and ruthenium compounds. From DNA damage to cancer chemotherapy
    Principal investigator: J. Kašpárková, 2006 - 2010
  • MŠMT.Center of Basic Research, ME, LC06030
    Biomolecular Center
    Coprincipal investigator: V. Brabec, 2006 - 2011
  • AV ČR, Program Nanotechnology for Society, KAN200200651
    Nanoparticle and supramolecular systems for targeted transport of therapeutic drugs,
    Coprincipal investigator: V. Brabec, 2007 - 2010.
  • GA AV ČR, IAA400040803
    Mechanistic studies related to targeted cancer chemotherapy with light-activated platinum and ruthenium antitumor agents
    Principal investigator: J. Kašpárková, 2008 - 2011
  • MŠMT ČR, Kontakt, ME08017
    Platinum metal complexes as DNA-protein cross-linking agents
    Principal investigator: V. Brabec, 2008 - 2010
  • MŠMT ČR, COST, OC08003
    Structure, recognition and processing of DNA damage by antitumor metal-based drugs
    Principal investigator: V. Brabec, 2008 - 2011
  • GA CR 301/09/H004
    Molecular and structural biology of selected antitumor drugs. From mechanistic studies to chemotherapy of tumors
    Principal investigator: V. Brabec, 2009 - 2012
  • AS CR M200040901
    Antitumor transition metal-based complexes. From mechanistic studies to cancer chemotherapy
    Principal investigator: J. Kašpárková, 2009 – 2013
  • GA CR P301/10/0598
    Metallodrugs based on osmium, platinum and ruthenium complexes. From mechanistic studies to novel, more efficient chemotherapy of cancor
    Principal investigator: V. Brabec, 2010 – 2014
  • GA CR P305/10/P143
    Isolation and identification of proteins in cancer cell extracts that bind to DNA modified by antitumor metallodrugs
    Principal investigator: P. Machalová, 2010 – 2012
  • MŠMT ČR, Kontakt, ME10066
    Transition metal-based anticancer compounds. From mechanistic studies to innovatory cancer chemotherapy
    Principal investigator: V. Brabec, 2010 – 2012
  • European Commission, FP7, ERC-2009-AdG_20090325
    Bioinorganic chemistry for the design of new medicines
    Co-principal investigator: V. Brabec, 2010 – 2015